Current Classification of Antiarrhythmic Drugs as a Guide to Their Rational Clinical Use
- 21 Downloads
The Harrison modification of the Vaughn Williams classification scheme for Class I antiarrhythmic drugs has been widely accepted. It has important clinical and electrophysiological bases, and recent membrane classification based on tightness of drug coupling to sodium channels in cardiac muscle and His-Purkinje tissue further supports the modification. This scheme enables the clinician to predict appropriate agents for patients with particular arrhythmia syndromes and to effectively combine drugs to treat life-threatening arrhythmias. As new drugs are tested and classified, it should continue to prove useful to electrophysiologists and arrhythmia specialists in the future.
KeywordsQuinidine Antiarrhythmic Drug Disopyramide Propafenone Mexiletine
Unable to display preview. Download preview PDF.
- Harrison DC (Ed.). Symposium on perspectives on the treatment of ventricular arrhythmias. American Journal of Cardiology 52: IC–2C, 1983Google Scholar
- Harrison DC, Winkle RA, Sami M, Mason JW. Encainide: a new and potent antiarrhythmic agent. In Harrison (Ed.) Cardiac arrhythmias: a decade of progress, pp. 315–330, G.K. Hall Medical Publishers, Boston, 1981Google Scholar
- Vaughn Williams EM. Classification of antiarrhythmic drugs. In Sandoe et al. (Eds) Cardiac arrhythmias, pp. 449–473, Ad Astra, Sodertalje, Sweden, 1970Google Scholar
- Vaughn Williams EM. Disopyramide. In Garfein (Ed.) Clinical pharmacology of cardiac antiarrhythmic agents: classical and current concepts reevaluated. Annals of the New York Academy of Sciences 432: 189–200, 1984Google Scholar